PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Staffan Skogvall | 45,57 | 45,57 | 2024-10-14 |
| Vict Th Engwalls Stiftelse | 2,29 | 2,29 | 2024-09-26 |
| Avanza Pension | 1,51 | 1,51 | 2024-09-26 |
| Arne Arvidsson | 1,43 | 1,43 | 2024-09-26 |
| Nordnet Pensionsförsäkring | 0,81 | 0,81 | 2024-09-26 |
| Tommy Johansson | 0,71 | 0,71 | 2024-09-26 |
| Staffan Engelbert Bodén | 0,64 | 0,64 | 2024-09-26 |
| Magnus Persson | 0,55 | 0,55 | 2024-09-26 |
| Merrick Lee Tabor | 0,53 | 0,53 | 2024-09-26 |
| Arne Skogvall | 0,52 | 0,52 | 2024-09-26 |
2024-11-21 Delårsrapport 2024-Q3
2025-02-20 Bokslutskommuniké 2024
